SMO and rheumatoid arthritis: To investigate the effect of Smo on RA-FLSs migration, FLSs cells were treated in the presence of Smo agonist (purmorphamine, 5 μmol/l) or Smo antagonist (KAAD-cyclopamine, 1 μmol/l).